
Figures

Figure 1:






Figure 2:

Figure 3:



A
P1
B
P2
C
The end of P2
MSC- Clinical product
Evaluation of three randomly chosen MSC-clinical products

Figure 4:



A
99.5%
CD73
99.8%
CD90
98.9%
CD105
96.7%
HLA-Class I
0.01%
CD45
0.3%
CD14
0.1%
CD34
0.8%
HLA-DR
Events
B
MSCs
Adipocytes (20x)
Osteoblasts (10x)

Figure 5:



A
MSCs (P2) from 4.4x10⁴ MSCs
2.0x10⁶
1.8x10⁶
1.5x10⁶
1.3x10⁶
1.0x10⁶
7.5x10⁵
5.0x10⁵
2.5x10⁵
0
ns ns
Donor 1
Donor 2
Donor 3
Donor 4
Donor 5
Donor 6
Donor 7
Donor 8
Mean
MSC-Pool
4 MSC-Aliquots of the MSC-Bank
B
Number of MSCs at the end of P2
8.0x10⁰⁸
6.0x10⁰⁸
4.0x10⁰⁸
2.0x10⁰⁸
0.0
MSC-148
MSC-79
MSC-40
MSC-120
MSC-180
MSC-20
MSC-60
MSC-100
MSC-140
MSC-160
0 2 4 6 8 10 12 14
Days in culture
Passage 1
Passage 2
C
Population doublings
10
8
6
4
2
0
P1
P2
CPDs
D
Number of PDs
6
5
4
3
2
1
0
-1
-2
P3 P4 P5 P6 P7 P8 P9 P10 P11 P12
Number of passages

Figure 6:



A
Inhibition of MNC-Proliferation (%)
120
100
80
60
40
20
0
P<0.001
P<0.01
Donor 1
Donor 2
Donor 3
Donor 4
Donor 5
Donor 6
Donor 7
Donor 8
MSC-Pool
Mean of 8 donors
MSC-140
B
Inhibition of MNC Proliferation (%)
100
80
60
40
20
0
MSC-20
MSC-60
MSC-100
MSC-160
MSC-180
MSC-140

Figure 7:




A
B
C
D
E
Cell number
Cell type (Classes)
29 2r
29 1r
39 3r
29 3r
49 4r
69 6r
69 4r
19 2r
8q24 x2
8q24 x1
8q24 x3
8q24 x4

Figure 8:


A
Fold change
6
5
4
3
2
1
0
MSC-140
MSC-160
MSC-180
Control
p21
p53
c-myc
B
Donor-specific genotype (%)
40
30
20
10
0
Donor 1
Donor 2
Donor 3
Donor 4
Donor 5
Donor 6
Donor 7
Donor 8